GW "Through The Pain" Of Zantac
Management at Glaxo Wellcome has reiterated its confidence in itsleading therapeutic franchises and commented that it is "through the pain" of Zantac (ranitidine) in a presentation to analysts Goldman Sachs.
Strong reassurances on margin progression have also resulted in GW remaining on the analysts' recommended list, and Goldman Sachs analysts believe that the company should be a core long-term portfolio holding which will deliver double-digit sales growth and a total return of approximately 17% from the second half of 1998 onwards.
The analysts believe that Zantac's US patent expiration on July 25 "is no longer relevant," as GW is currently the world leader in respiratory and antiviral treatments, due to key new product drivers (Marketletter August 11). The analysts claim that GW's portfolio is looking strong, with no further significant patent expiries due until 2003, and believe that the company has a better safety profile than competitors such as SmithKline Beecham and Zeneca.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze